Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes. A post hoc analysis from the REWIND randomized trial

Digital

Autores:
Raubenheimer, Peter J.
Cushman, William C.
Avezum, Alvaro
Basile, Jan
Conget, Ignacio
Dagenais, Gilles
Hoover, Anastasia
Jansky, Petr
Lanas, Fernando
Leiter, Lawrence A.
Lopez-Jaramillo, Patricio
Pogosova, Nana
Probstfield, Jeffrey
Rao-Melacini, Purnima
Ryden, Lars
Sheu, Wayne H.-H.
Temelkova-Kurktschiev, Theodora
Gerstein, Hertzel C.
Tipo de recurso:
Article of journal
Fecha de publicación:
2022
Institución:
Universidad de Santander
Repositorio:
Repositorio Universidad de Santander
Idioma:
eng
OAI Identifier:
oai:repositorio.udes.edu.co:001/6086
Acceso en línea:
https://doi.org/10.1111/dom.14634
https://repositorio.udes.edu.co/handle/001/6086
Palabra clave:
Rights
closedAccess
License
© The Authors, John Wiley & Sons Ltd. 2022
id RUDES2_90d1c4976d1ded2ddd57846038a39e9f
oai_identifier_str oai:repositorio.udes.edu.co:001/6086
network_acronym_str RUDES2
network_name_str Repositorio Universidad de Santander
repository_id_str
dc.title.spa.fl_str_mv Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes. A post hoc analysis from the REWIND randomized trial
title Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes. A post hoc analysis from the REWIND randomized trial
spellingShingle Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes. A post hoc analysis from the REWIND randomized trial
title_short Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes. A post hoc analysis from the REWIND randomized trial
title_full Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes. A post hoc analysis from the REWIND randomized trial
title_fullStr Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes. A post hoc analysis from the REWIND randomized trial
title_full_unstemmed Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes. A post hoc analysis from the REWIND randomized trial
title_sort Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes. A post hoc analysis from the REWIND randomized trial
dc.creator.fl_str_mv Raubenheimer, Peter J.
Cushman, William C.
Avezum, Alvaro
Basile, Jan
Conget, Ignacio
Dagenais, Gilles
Hoover, Anastasia
Jansky, Petr
Lanas, Fernando
Leiter, Lawrence A.
Lopez-Jaramillo, Patricio
Pogosova, Nana
Probstfield, Jeffrey
Rao-Melacini, Purnima
Ryden, Lars
Sheu, Wayne H.-H.
Temelkova-Kurktschiev, Theodora
Gerstein, Hertzel C.
dc.contributor.author.none.fl_str_mv Raubenheimer, Peter J.
Cushman, William C.
Avezum, Alvaro
Basile, Jan
Conget, Ignacio
Dagenais, Gilles
Hoover, Anastasia
Jansky, Petr
Lanas, Fernando
Leiter, Lawrence A.
Lopez-Jaramillo, Patricio
Pogosova, Nana
Probstfield, Jeffrey
Rao-Melacini, Purnima
Ryden, Lars
Sheu, Wayne H.-H.
Temelkova-Kurktschiev, Theodora
Gerstein, Hertzel C.
dc.contributor.researchgroup.spa.fl_str_mv Masira
description Digital
publishDate 2022
dc.date.accessioned.none.fl_str_mv 2022-02-21T20:58:39Z
dc.date.available.none.fl_str_mv 2022-02-21T20:58:39Z
dc.date.issued.none.fl_str_mv 2022-01-04
dc.type.spa.fl_str_mv Artículo de revista
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.spa.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.content.spa.fl_str_mv Text
dc.type.driver.spa.fl_str_mv info:eu-repo/semantics/article
dc.type.redcol.spa.fl_str_mv http://purl.org/redcol/resource_type/ART
dc.type.version.spa.fl_str_mv info:eu-repo/semantics/publishedVersion
format http://purl.org/coar/resource_type/c_6501
status_str publishedVersion
dc.identifier.doi.none.fl_str_mv https://doi.org/10.1111/dom.14634
dc.identifier.uri.none.fl_str_mv https://repositorio.udes.edu.co/handle/001/6086
url https://doi.org/10.1111/dom.14634
https://repositorio.udes.edu.co/handle/001/6086
dc.language.iso.spa.fl_str_mv eng
language eng
dc.relation.citationissue.spa.fl_str_mv 4
dc.relation.citationvolume.spa.fl_str_mv 23
dc.relation.indexed.spa.fl_str_mv Scopus
dc.relation.ispartofjournal.spa.fl_str_mv Diabetes, Obesity and Metabolism
dc.rights.spa.fl_str_mv © The Authors, John Wiley & Sons Ltd. 2022
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_14cb
dc.rights.accessrights.spa.fl_str_mv info:eu-repo/semantics/closedAccess
dc.rights.creativecommons.spa.fl_str_mv Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)
dc.rights.uri.spa.fl_str_mv https://creativecommons.org/licenses/by-nc/4.0/
rights_invalid_str_mv © The Authors, John Wiley & Sons Ltd. 2022
Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)
https://creativecommons.org/licenses/by-nc/4.0/
http://purl.org/coar/access_right/c_14cb
eu_rights_str_mv closedAccess
dc.format.mimetype.spa.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Diabetes, Obesity and Metabolism
dc.publisher.place.spa.fl_str_mv Reino Unido
dc.source.spa.fl_str_mv https://dom-pubs.onlinelibrary.wiley.com/doi/epdf/10.1111/dom.14634
institution Universidad de Santander
bitstream.url.fl_str_mv https://repositorio.udes.edu.co/bitstreams/822375db-8f67-4737-ab25-bf711d73b662/download
https://repositorio.udes.edu.co/bitstreams/92d08648-b614-43dd-97c3-f481b997a1a0/download
https://repositorio.udes.edu.co/bitstreams/6e8981f5-1c6c-4df2-a1d4-17e3326684c1/download
https://repositorio.udes.edu.co/bitstreams/4d29ea38-4f7e-428c-b99b-985ea0d20562/download
bitstream.checksum.fl_str_mv aa2371097f345c34904e34901f99d039
38d94cf55aa1bf2dac1a736ac45c881c
5dbe86c1111d64f45ba435df98fdc825
913f3f27e87e55f77753a7eae5667a59
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Universidad de Santander
repository.mail.fl_str_mv soporte@metabiblioteca.com
_version_ 1814158970957332480
spelling Raubenheimer, Peter J.260f749c-e594-4273-a34d-e926010f883c-1Cushman, William C.6e873915-69b2-4696-afa0-6d21bbeb3531-1Avezum, Alvaro8b920360-abb2-4ec8-b5ee-4e3f4e0b11eb-1Basile, Jan31df2eea-b661-4757-98a0-111336270810-1Conget, Ignacioc0327a53-3097-438b-9a40-d441f3c20758-1Dagenais, Gillesc865f015-4dc7-483d-9dae-132288d901f8-1Hoover, Anastasia4af8a82b-9f2a-4b54-97b6-f0d2a9d846d8-1Jansky, Petrbf8ec62a-6edc-439c-a698-2e4fa4172f04-1Lanas, Fernandod22b7fe4-9f1f-4028-a22b-be782ef03d3c-1Leiter, Lawrence A.bcdd3211-40b7-474d-9f6c-8a1051ceb9bf-1Lopez-Jaramillo, Patricio9a71267b-dcb0-4d31-b37d-2d30be58d4d2-1Pogosova, Nana0f2fb5e5-6659-4562-96e6-74c03e0c46bf-1Probstfield, Jeffreycce7af47-ba6b-4280-bbb5-4c0a46da5d7d-1Rao-Melacini, Purnima4a704681-2187-4ddd-b2c1-f8e681c77274-1Ryden, Larse8666dad-aab3-446a-9e58-5e23a391873f-1Sheu, Wayne H.-H.d377b549-9728-486e-820f-f5e9d3ba834b-1Temelkova-Kurktschiev, Theodoraa08e998d-95f2-4139-ae16-bd8009965b60-1Gerstein, Hertzel C.8dbb4c88-f0dd-45f2-8bc4-590f0a1e3c3c-1Masira2022-02-21T20:58:39Z2022-02-21T20:58:39Z2022-01-04DigitalAim To assess the occurrence of atrial fibrillation or atrial flutter (atrial arrhythmias [AA]) in patients with type 2 diabetes treated with once-weekly subcutaneous dulaglutide versus placebo. Materials and Methods Patients without electrocardiographic (ECG)-confirmed AA at baseline and randomized in the REWIND trial were assessed for the development of AA based on an annual ECG. Additional analyses included whether dulaglutide compared with placebo reduced the composite outcome of AA or death, AA or cardiovascular death, AA or stroke and AA or heart failure. Results Among 9543 participants (mean age 66 ± 7 years, with cardiovascular risk factors and 31% with previous cardiovascular disease) without AA at entry in the trial, 524 patients (5.5%) had at least one episode of AA during the median 5.4 years of follow-up. Incident AA occurred in 269 of the 4769 participants allocated to dulaglutide (5.6%), at a rate of 10.7 per 1000 person-years, versus 255 of the 4774 allocated to placebo (5.3%), at a rate of 10.5 per 1000 person-years (P = .59). There was also no effect of dulaglutide on the composite outcome of AA and death or AA and heart failure. Conclusion This post hoc analysis of data from the REWIND trial showed that treatment with dulaglutide was not associated with a reduced incidence of AA in this at-risk group of patients with type 2 diabetes.Ciencias Médicas y de la Saludapplication/pdfhttps://doi.org/10.1111/dom.14634https://repositorio.udes.edu.co/handle/001/6086engDiabetes, Obesity and MetabolismReino Unido423ScopusDiabetes, Obesity and Metabolism© The Authors, John Wiley & Sons Ltd. 2022info:eu-repo/semantics/closedAccessAtribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)https://creativecommons.org/licenses/by-nc/4.0/http://purl.org/coar/access_right/c_14cbhttps://dom-pubs.onlinelibrary.wiley.com/doi/epdf/10.1111/dom.14634Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes. A post hoc analysis from the REWIND randomized trialArtículo de revistahttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articlehttp://purl.org/redcol/resource_type/ARTinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85Todas las AudienciasPublicationORIGINALDulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes. A post hoc analysis from the REWIND randomized trial.pdfDulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes. A post hoc analysis from the REWIND randomized trial.pdfapplication/pdf258879https://repositorio.udes.edu.co/bitstreams/822375db-8f67-4737-ab25-bf711d73b662/downloadaa2371097f345c34904e34901f99d039MD51LICENSElicense.txtlicense.txttext/plain; charset=utf-859https://repositorio.udes.edu.co/bitstreams/92d08648-b614-43dd-97c3-f481b997a1a0/download38d94cf55aa1bf2dac1a736ac45c881cMD52TEXTDulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes. A post hoc analysis from the REWIND randomized trial.pdf.txtDulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes. A post hoc analysis from the REWIND randomized trial.pdf.txtExtracted texttext/plain5https://repositorio.udes.edu.co/bitstreams/6e8981f5-1c6c-4df2-a1d4-17e3326684c1/download5dbe86c1111d64f45ba435df98fdc825MD53THUMBNAILDulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes. A post hoc analysis from the REWIND randomized trial.pdf.jpgDulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes. A post hoc analysis from the REWIND randomized trial.pdf.jpgGenerated Thumbnailimage/jpeg7507https://repositorio.udes.edu.co/bitstreams/4d29ea38-4f7e-428c-b99b-985ea0d20562/download913f3f27e87e55f77753a7eae5667a59MD54001/6086oai:repositorio.udes.edu.co:001/60862023-10-09 16:51:29.74https://creativecommons.org/licenses/by-nc/4.0/© The Authors, John Wiley & Sons Ltd. 2022https://repositorio.udes.edu.coRepositorio Universidad de Santandersoporte@metabiblioteca.comTGljZW5jaWEgZGUgUHVibGljYWNpw7NuIFVERVMKRGlyZWN0cmljZXMgZGUgVVNPIHkgQUNDRVNPCgo=